Dr Zakharia on Real-World Outcomes With First-Line Axitinib

Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.

Related Keywords

Yousef Zakharia , University Of Iowa Hospitals , International Metastatic , University Of Iowa , Database Consortium , Iowa Hospitals , International Kidney Cancer Symposium , Onclive Tv , Genitourinary Cancer ,